Abstract
Hepatic fibrosis, or scarring of the liver, is emerging as a treatable complication of advanced liver disease, following significant progress in understanding its underlying mechanisms. Efforts have focused on the hepatic stellate cell, as these cells can undergo 'activation' into proliferative and fibrogenic myofibroblast-like cells during liver injury. Stimuli driving stellate cell activation include hepatocellular necrosis due to oxidant stress, apoptosis, and soluble growth factors. Specific lymphocyte subsets can also stimulate fibrogenesis. A cascade of signaling and transcriptional events in stellate cells underlies the fibrogenic response to liver injury, with each step in the cascade being a potential target for antifibrotic therapy. Disease-specific fibrogenic mechanisms have also been uncovered: in hepatitis C, this may include direct stimulation of stellate cell activation by viral infection; in nonalcoholic steatohepatitis, elevated levels of leptin and increased leptin signaling by stellate cells increase fibrogenesis. Determinants of fibrosis progression include both environmental and genetic factors, with ongoing efforts to define specific polymorphisms correlating with fibrosis progression rates. Human studies now indicate that fibrosis and even cirrhosis could be reversible, especially if the underlying disease is eradicated. A key challenge is to establish noninvasive means of assessing fibrosis stage and progression using either serum tests and/or imaging. In addition, endpoints of antifibrotic clinical trials need to be established so that reliable evidence of benefit can be identified. We are on the cusp of a new era in which antifibrotic therapies could become important in treating chronic fibrosing liver disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Friedman SL (2000) Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275: 2247–2250
Schuppan D et al. (2001) Matrix as modulator of stellate cell and hepatic fibrogenesis. Semin Liver Dis 21: 351–372
Geerts A (2001) History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 21: 311–335
Pinzani M and Marra F (2001) Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 21: 397–416
Rockey D (2003) Vascular mediators in the injured liver. Hepatology 37: 4–12
Kinnman N et al. (2003) The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab Invest 83: 163–173
Cassiman D et al. (2002) Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol 36: 200–209
Corpechot C et al. (2002) Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 35: 1010–1021
Forbes SJ et al. (2004) A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 126: 955–963
Magness ST et al. (2004) A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology 40: 1151–1159
Kalluri R and Neilson EG (2003) Epithelial–mesenchymal transition and its implications for fibrosis. J Clin Invest 112: 1776–1784
Tsukamoto H (2002) Redox regulation of cytokine expression in Kupffer cells. Antioxid Redox Signal 4: 741–748
Bataller R et al. (2003) NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 112: 1383–1394
Tuma DJ (2002) Role of malondialdehyde–acetaldehyde adducts in liver injury. Free Radic Biol Med 32: 303–308
Canbay A et al. (2003) Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 83: 655–663
Canbay A et al. (2002) Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 123: 1323–1330
LeCouter J et al. (2003) Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 299: 890–893
Olaso E et al. (2003) Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis. Hepatology 37: 674–685
Marra F (2002) Chemokines in liver inflammation and fibrosis. Front Biosci 7: d1899–d1914
Yoshiji H et al. (2003) Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 52: 1347–1354
Ankoma-Sey et al. (2000) Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells. Hepatology 31: 141–148
Schwabe RF et al. (2003) Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am J Physiol Gastrointest Liver Physiol 285: G949–G958
Bataller R et al. (2004) Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 126: 529–540
Efsen E et al. (2002) Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. J Hepatol 37: 39–47
Paik YH et al. (2003) Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 37: 1043–1055
Kobayashi S et al. (2003) Apoptosis of T cells in the hepatic fibrotic tissue of the rat: a possible inducing role of hepatic myofibroblast-like cells. Cell Tissue Res 311: 353–364
Shi Z et al. (1997) Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci USA 94: 10663–10668
Hillebrandt S et al. (2002) Genome-wide analysis of hepatic fibrosis in inbred mice identifies the susceptibility locus Hfib1 on chromosome 15. Gastroenterology 123: 2041–2051
Safadi R et al. (2004) Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 127: 870–882
Rachfal AW and Brigstock DR (2003) Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis. Hepatol Res 26: 1–9
Mann DA and Smart DE (2002) Transcriptional regulation of hepatic stellate cell activation. Gut 50: 891–896
Hellemans K et al. (2003) Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology 124: 184–201
Marra F et al. (2000) Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 119: 466–478
Miyahara T et al. (2000) Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 275: 35715–35722
Hellemans K et al. (2004) Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids. Hepatology 39: 97–108
Kalinichenko VV et al. (2003) Foxf1 +/− mice exhibit defective stellate cell activation and abnormal liver regeneration following CCl4 injury. Hepatology 37: 107–117
Yang C et al. (2003) Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology 124: 147–159
Bonacchi A et al. (2003) The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. Gastroenterology 125: 1060–1076
Pohlmann S et al. (2003) Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol 77: 4070–4080
Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346: 1221–1031
Ikejima K et al. (2002) Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 122: 1399–1410
Leclercq IA et al. (2002) Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 37: 206–213
Saxena NK et al. (2003) Leptin induces increased alpha2(I) collagen gene expression in cultured rat hepatic stellate cells. J Cell Biochem 89: 311–320
Kamada Y et al. (2003) Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125: 1796–1807
Bonis PA et al. (2001) Is liver fibrosis reversible? N Engl J Med 344: 452–454
Desmet VJ and Roskams T (2004) Cirrhosis reversal: a duel between dogma and myth. J Hepatol 40: 860–867
Poynard T et al. (2002) Impact of pegylated interferon alpha-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122: 1303–1313
Murphy FR et al. (2002) Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 277: 11069–11076
Wanless IR et al. (2000) Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 124: 1599–1607
Issa R et al. (2004) Spontaneous recovery from micronodular cirrhosis: Evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 126: 1795–1808
Bataller R et al. (2003) Genetic polymorphisms and the progression of liver fibrosis: A critical appraisal. Hepatology 37: 493–503
Albanis E and Friedman SL (2002) Non-invasive markers of hepatic fibrosis. Clin Perspect Gastroenterol 5: 182–187
Callewaert N et al. (2004) Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 10: 429–434
Pinzani M and Rombouts K (2004) Liver fibrosis: from the bench to clinical targets. Dig Liver Dis 36: 231–242
Schuppan D and Porov Y (2002) Hepatic fibrosis: From bench to bedside. J Gastroenterol Hepatol 17 (Suppl 3): S300–S305
Friedman SL and Arthur MJP (2002) Reversing hepatic fibrosis. Sci Med 8: 194–205
Acknowledgements
The author's studies are supported by grants from the NIDDK, the Feld Foundation and the US Department of Defense. I wish to acknowledge the many outstanding publications from colleagues in the field whose work could not be cited because of space constraints.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Friedman, S. Mechanisms of Disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat Rev Gastroenterol Hepatol 1, 98–105 (2004). https://doi.org/10.1038/ncpgasthep0055
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep0055
This article is cited by
-
MicroRNA-29a-3p prevents Schistosoma japonicum-induced liver fibrosis by targeting Roundabout homolog 1 in hepatic stellate cells
Parasites & Vectors (2023)
-
Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis
Nature Communications (2023)
-
Frequency of infiltrating regulatory T-cells in the portal tract of biliary atresia
Pediatric Surgery International (2023)
-
Targeting necroptosis in fibrosis
Molecular Biology Reports (2023)
-
Loss of FOXA2 induces ER stress and hepatic steatosis and alters developmental gene expression in human iPSC-derived hepatocytes
Cell Death & Disease (2022)